

**THC BIOMED INTL LTD.**

**(formerly Thelon Capital Ltd.)**

**Condensed Interim Consolidated Financial Statements**

**For the Six Months Ended January 31, 2016**

**(Expressed in Canadian Dollars)**

**(Unaudited)**

---

**THC BIOMED INTL LTD.**  
**(formerly Thelon Capital Ltd.)**

**Condensed Interim Consolidated Financial Statements**  
**(Unaudited)**

---

<b>For the Six Months Ended January 31, 2016</b>	<b>Page</b>
Notice to Readers	3
Condensed Interim Consolidated Statements of Financial Position	4
Condensed Interim Consolidated Statements of Comprehensive Loss	5
Condensed Interim Consolidated Statements of Changes in Equity	6
Condensed Interim Consolidated Statements of Cash Flows	7
Notes to the Condensed Interim Consolidated Financial Statements	8 – 33

### **Notice to Readers**

Under National Instrument 51-102, Part 4.3(3)(a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of THC BioMed Intl Ltd. (formerly Thelon Capital Ltd.) for the six months ended January 31, 2016 have been prepared in accordance with International Accounting Standard 34 for Interim Financial Reporting under International Financial Reporting Standards. These condensed interim consolidated financial statements are the responsibility of the Company's management and have been approved by the Board of Directors. The Company's independent auditors have not performed an audit or review of these condensed interim consolidated financial statements.

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Condensed Interim Consolidated Statements of Financial Position**  
(Expressed in Canadian Dollars)  
(Unaudited)

As at	January 31 2016	July 31 2015
<b>Assets</b>		
<b>Current</b>		
Cash	\$ 46,173	\$ 51,710
Amounts receivable	13,488	50
Goods and services tax receivable	15,322	44,467
Investment held for sale (note 5)	-	3,150
Advances to related parties (note 11)	98,054	100,604
Prepaid expenses and deposits	40,913	33,058
	<b>213,950</b>	<b>233,039</b>
<b>Non-current</b>		
Property and equipment (note 6)	1,085,498	1,034,388
	<b>\$ 1,299,448</b>	<b>\$ 1,267,427</b>
<b>Liabilities</b>		
<b>Current</b>		
Accounts payable and accrued liabilities	\$ 556,821	\$ 1,456,072
Deferred revenues	-	250,000
Current portion of mortgage payable (note 7)	22,344	22,878
Promissory notes payable	-	198,915
Advances from related parties (note 11)	74,754	126,165
	<b>653,919</b>	<b>2,054,030</b>
<b>Non-current</b>		
Promissory note payable (note 8 and 11)	135,000	301,095
Mortgage payable (note 7)	413,528	427,006
	<b>548,528</b>	<b>728,101</b>
	<b>1,202,447</b>	<b>2,782,131</b>
<b>Shareholders' Equity</b>		
Share capital (note 9)	3,517,164	1,734,048
Reserves	109,310	59,754
Accumulated deficit	(3,529,473)	(3,308,506)
	<b>97,001</b>	<b>(1,514,704)</b>
	<b>\$ 1,299,448</b>	<b>\$ 1,267,427</b>

**Nature and continuance of operations** (note 1)

**Subsequent events** (note 16)

These condensed interim consolidated financial statements were authorized for issue by the Board of Directors on March 31, 2016. They are signed on the Company's behalf by:

"John Miller"

Director

"Jason Walsh"

Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Condensed Interim Consolidated Statements of Comprehensive Loss**  
(Expressed in Canadian Dollars)  
(Unaudited)

	For the three months ended		For the six months ended	
	January 31 2016	January 31 2015	January 31 2016	January 31 2015
<b>Revenue</b>				
Consulting fees	\$ 250,000	\$ -	\$ 250,000	\$ -
<b>Expenses</b>				
Advertising and promotion	13,031	5,379	26,998	6,213
Automobile expenses	5,498	7,042	10,724	13,938
Bank charges and interest	7,539	2,269	33,661	6,608
Consulting (note 11)	75,500	47,687	122,000	73,025
Depreciation	3,399	761	6,799	1,085
Investor relation expenses	6,163	3,002	9,783	3,002
Laboratory expenses	8,623	16,637	18,643	33,580
Legal and accounting (note 11)	68,945	45,867	99,702	75,058
Licenses, dues, and subscriptions	-	198	-	1,438
Office and administration (note 11)	14,325	20,047	31,540	28,663
Salaries and benefits (note 11)	81,125	79,114	153,902	150,086
Share-based compensation (note 10)	7,588	-	62,252	-
Telephone	2,073	2,201	6,541	2,357
Transfer agent and filing fees	9,634	5,772	12,797	5,772
Travel	10,394	12,095	15,329	18,903
	<b>313,837</b>	<b>248,071</b>	<b>610,671</b>	<b>419,728</b>
<b>Other (income) expense items</b>				
Foreign exchange loss	2	-	3	7,420
Forgiveness of debt settlements	(125,303)	-	(125,303)	-
Gain on sale of investment	(1,575)	-	(1,575)	-
Interest income	(51)	(15)	(133)	(15)
Listing expense (note 2)	-	1,062,815	-	1,062,815
	<b>(126,927)</b>	<b>1,062,800</b>	<b>(127,008)</b>	<b>1,070,220</b>
<b>Net and comprehensive loss for the period</b>	<b>\$ 63,090</b>	<b>\$ (1,310,871)</b>	<b>\$ (233,663)</b>	<b>\$ (1,489,948)</b>
<b>Basic and diluted loss per share</b>	<b>\$ 0.00</b>	<b>\$ (0.05)</b>	<b>\$ (0.00)</b>	<b>\$ (0.06)</b>
<b>Weighted average number of shares outstanding</b>	<b>89,135,157</b>	<b>28,151,506</b>	<b>82,519,279</b>	<b>23,424,940</b>

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Condensed Interim Consolidated Statements of Changes in Equity**  
(Expressed in Canadian Dollars)  
(Unaudited)

	Number of Shares	Share Capital	Share Subscriptions Receivable	Share-Based Payment Reserve	Deficit	Total Equity
Balance at July 31, 2015	75,674,620	\$ 1,734,048	\$ -	\$ 59,754	\$ (3,308,506)	\$ (1,514,704)
Shares issued for cash	10,675,000	1,090,500	-	-	-	1,090,500
Shares issued for debt	6,359,924	706,516	-	-	-	706,516
Shares issued for finder fees	240,000	23,400	-	-	-	23,400
Share issuance costs	-	(62,300)	-	-	-	(62,300)
Stock options exercised	250,000	25,000	-	-	-	25,000
Share-based compensation	-	-	-	62,252	-	62,252
Reverse fair value of stock options exercised and cancelled	-	-	-	(12,696)	12,696	-
Loss for the period	-	-	-	-	(233,663)	(233,663)
<b>Balance at January 31, 2016</b>	<b>93,199,544</b>	<b>\$ 3,517,164</b>	<b>\$ -</b>	<b>\$ 109,310</b>	<b>\$ (3,529,473)</b>	<b>\$ 97,001</b>
Balance at July 31, 2014	23,040	\$ 138,221	\$ (115)	\$ -	\$ (246,450)	\$ (108,344)
Shares issued for cash as a private company	4,546	820,000	-	-	-	820,000
Share issuance costs as a private company	-	(65,600)	-	-	-	(65,600)
Subscriptions received	-	-	115	-	-	115
Share restructuring (note 2)	56,948,660	-	-	-	-	-
Shares issued for acquisition of Thelon Capital Ltd. (note 2)	18,698,374	841,427	-	-	-	841,427
Loss for the period	-	-	-	-	(1,458,931)	(1,458,931)
Balance at January 31, 2015	75,674,620	\$ 1,734,048	\$ -	\$ -	\$ (1,705,381)	\$ 28,667

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Condensed Interim Consolidated Statements of Cash Flows**  
(Expressed in Canadian Dollars)  
(Unaudited)

	For the three months ended		For the six months ended	
	January 31	January 31	January 31	January 31
	2016	2015	2016	2015
<b>Cash provided by (used for)</b>				
<b>Operating activities</b>				
Net loss for the period	\$ 63,090	\$ (1,279,854)	\$ (233,663)	\$ (1,458,931)
Add items not affecting cash				
Accrued interest revenue	(49)	(11)	(98)	(11)
Accrued liabilities	(61,719)	(1,213)	22,950	6,092
Depreciation	3,399	761	6,799	1,085
Foreign exchange loss	2	-	3	7,420
Listing expense	-	1,062,815	-	1,062,815
Share-based compensation	7,588	-	62,252	-
Shares issued for finance costs	-	-	14,175	-
	12,311	(217,502)	(127,582)	(381,530)
Net change in non-cash working capital	(595,325)	30,446	(562,520)	27,138
	(583,014)	(187,056)	(690,102)	(354,392)
<b>Financing activities</b>				
Advances from (repaid to) related parties	(77,096)	88,151	(36,411)	82,809
Issuance of shares for cash, net of share issuance costs	907,000	138,225	1,076,600	892,619
Share subscription received	-	7	-	115
Mortgage proceeds repaid	(4,548)	(5,755)	(14,012)	(5,764)
Promissory notes repaid	(188,754)	-	(289,400)	(173,227)
	636,602	220,628	736,777	796,552
<b>Investing activities</b>				
Acquisition of property and equipment	(27,205)	(141,183)	(57,909)	(271,393)
Advances to related parties	9,470	-	2,550	-
Disposition of investment held for sale	3,150	-	3,150	-
	(14,585)	(141,183)	(52,209)	(271,393)
<b>Effect of foreign exchange translation on cash</b>	(2)	-	(3)	(7,420)
<b>Net increase (decrease) in cash</b>	<b>39,001</b>	<b>(107,611)</b>	<b>(5,537)</b>	<b>163,347</b>
<b>Cash (cheques written in excess of bank balances), beginning of period</b>	<b>7,172</b>	<b>257,772</b>	<b>51,710</b>	<b>(13,186)</b>
<b>Cash, end of period</b>	<b>\$ 46,173</b>	<b>\$ 150,161</b>	<b>\$ 46,173</b>	<b>\$ 150,161</b>

Supplemental cash flow information (note 13)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**1. NATURE AND CONTINUANCE OF OPERATIONS**

THC BioMed Intl Ltd. (the “Company”), formerly Thelon Capital Ltd. (“Thelon”) was formed by a reverse take-over (“RTO”) on January 14, 2015, by the shareholders of THC BioMed Ltd. and THC Meds Inc. (collectively the “THC Companies”).

THC BioMed Intl Ltd. is a public company incorporated under the Company Act of British Columbia on February 2, 1982. The Company traded on the TSX Venture Exchange from February 4, 2010 until December 22, 2014 when the Company requested the Company’s common shares be delisted. The Company also consolidated its share capital on a six old for one new basis on December 23, 2014. All references to share and per share amounts in these consolidated financial statements have been adjusted to reflect the share consolidation on a retrospective basis. On April 29, 2015, the Company was relisted and began trading on the Canadian Securities Exchange (“CSE”) under the symbol THC.

On February 21, 2016, THC BioMed Ltd. received its license to grow medical marijuana. THC BioMed Ltd. intends to cultivate medical marijuana and conduct scientific research and development in order to offer products and services through two revenue streams: (a) medical marijuana sales to other MMPR licensed producers; and (b) products and services related to medical marijuana.

The Company’s corporate office and principal place of business is at Suite 1100 – 888 Dunsmuir Street, Vancouver, British Columbia, Canada, V6C 3K4.

These condensed interim consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The continuing operations of the Company are dependent upon its ability to raise adequate financing to commence profitable operations in the future. To date the Company is considered to be in the development stage. These factors create material uncertainty that cast significant doubt about the Company being able to continue as a going concern. These condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. Further discussion of liquidity risk has been disclosed in Note 15c.

**2. REVERSE TAKE-OVER OF THELON CAPITAL LTD.**

On January 14, 2015, the Company entered into a Share Exchange Agreement between the Company, THC BioMed Ltd. and THC Meds Inc. and the shareholders of the THC Companies which resulted in a Reverse Take-Over transaction for accounting purposes. Pursuant to the agreement, 44,612,736 common shares of the Company were issued on January 14, 2015 and on January 22, 2015, 12,363,510 common shares of the Company were issued. There are an additional 26,833,751 shares that may be issued to the former shareholders of the THC Companies: 16,600,000 common shares of the Company are to be released in the event a license pursuant to Canada’s *Marihuana for Medical Purposes Regulations* (“MMPR”) is received by one of the two subsidiaries; and 10,233,751 common shares of the Company to be released pending the removal of certain potential liabilities of the THC Companies.



---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**2. REVERSE TAKE-OVER OF THELON CAPITAL LTD. (continued)**

As a result of the RTO transaction, the THC Companies' shareholders control the Company and Thelon's name was changed to THC BioMed Intl Ltd. Since the mining exploration business of Thelon had been suspended, Thelon did not meet the definition of a business and the transaction was accounted for as the purchase of Thelon's net assets by the THC Companies. The net asset purchase price was determined as an equity settled share-based payment under *IFRS 2, Share-Based Payment*, at the fair value of the equity instruments of the Company retained by the shareholders of Thelon, based on the market value of the Company's common shares on the date the Company's stock last traded.

The transaction costs relating to the RTO plus the aggregate of the fair value of the consideration paid and the net liabilities acquired has been recognized as listing expenses in the consolidated statement of loss and comprehensive loss. There are no costs pertaining to the former mineral operations of Thelon after the date of the RTO and there are no prior operating revenues or costs of Thelon included in these consolidated financial statements.

The breakdown of listing expenses in the consolidated statement of loss and comprehensive loss is as follows:

---

Purchase price of equity acquired	
18,698,374 common shares of Thelon Capital Ltd. at \$0.045 per share	\$ 841,427
<hr/>	
Total of share-based payments	841,427
Cash acquired	(267,398)
Other working capital deficit acquired	488,786
<hr/>	
Listing expenses	\$ 1,062,815

---

**3. BASIS OF PREPARATION**

**a) Basis of presentation**

These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, *Interim Financial Reporting* ("IAS34") as issued by the International Accounting Standards Board ("IASB") using accounting policies consistent with International Financial Reporting Standards ("IFRS").

These condensed interim consolidated financial statements have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**3. BASIS OF PREPARATION** (continued)

**b) Basis of consolidation**

These condensed interim consolidated financial statements include the accounts of the Company and its two subsidiaries on a consolidated basis after elimination of intercompany transactions and balances. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity.

**c) Foreign currencies**

**i) Presentation and functional currency**

The presentation and functional currency of the Company is the Canadian Dollar.

**ii) Foreign currency transactions**

Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the dates of the transactions. At each financial position date, monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at the date of the statement of financial position. Foreign exchange differences are recognized in the statement of comprehensive loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

**d) Significant accounting judgments and estimates**

The preparation of the condensed interim consolidated financial statements using accounting policies consistent with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. The preparation of the consolidated financial statements also requires management to exercise judgment in the process of applying the accounting policies.

**i) Critical accounting estimates**

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively from the period in which the estimates are revised. The following are the key estimate and assumption uncertainties that have a significant risk of resulting in a material adjustment within the next financial year:

**(a) Impairment of non-financial assets**

When there are indications that an asset may be impaired, the Company is required to estimate the asset's recoverable amount. Recoverable amount is the greater of value in use and fair value less costs to sell. Determining the value in use requires the Company to estimate expected future cash flows associated with the asset and a suitable discount rate in order to calculate present value. For the six months ended January 31, 2016, impairments of non-financial assets were \$Nil (January 31, 2015 – \$Nil).

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**3. BASIS OF PREPARATION** (continued)

**d) Significant accounting judgments and estimates** (continued)

**(b) Share-based compensation**

Management is required to make certain estimates when determining the fair value of stock options awards, and the number of awards that are expected to vest. These estimates affect the amount recognized as share-based compensation in the Company's statements of comprehensive loss. For the six months ended January 31, 2016, the Company recognized share-based compensation expense of \$62,252 (January 31, 2015 - \$Nil).

**ii) Critical judgments used in applying accounting policies**

In the preparation of these condensed interim consolidated financial statements, management has made judgments, aside from those that involve estimates, in the process of applying the accounting policies. These judgments can have an effect on the amounts recognized in the consolidated financial statements:

**(a) Acquisition of THC BioMed Ltd. and THC Meds Inc.**

The determination that the acquisition of the THC Companies constituted a Reverse Take-Over transaction and the subsequent allocation of the listing expense required judgment.

**(b) Purchase price allocation**

The allocation of the purchase price and subsequent costs between land and building required judgment. The allocation was determined using the property tax assessments when the properties were acquired.

**(c) Income taxes**

The measurement of deferred income tax assets requires management to make judgments in the interpretation and application of the relevant tax laws. The actual amount of income taxes only becomes final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the audited annual financial statements.

**4. SIGNIFICANT ACCOUNTING POLICIES**

**a) Financial instruments**

Financial assets and financial liabilities are recognized in the statements of financial position when the Company becomes a party to the contractual provisions of the financial instrument. The Company does not have any derivative financial instruments.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

**a) Financial instruments (continued)**

**i) Financial assets**

The Company classifies its financial assets into categories, at initial recognition, depending on the purpose for which the asset was acquired. The Company's accounting policy for each category is as follows:

**(a) Fair value through profit or loss**

This category comprises derivatives or financial assets acquired or incurred principally for the purpose of selling or repurchasing in the near term. They are carried in the statements of financial position at fair value, with changes in fair value recognized in profit or loss in the statement of comprehensive loss. Investments held for sale are classified as a fair value through profit and loss financial asset.

**(b) Loans and receivables**

These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are carried at amortized cost using the effective interest rate method less any provision for impairment. Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default. The Company has classified cash, amounts receivable, advances to related parties, and deposits as loans and receivables.

**(c) Held-to-maturity investments**

These assets are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Company's management has the positive intention and ability to hold to maturity. These assets are measured at amortized cost using the effective interest rate method.

If there is objective evidence that the investment is impaired, determined by reference to external credit ratings and other relevant indicators, the financial asset is measured at the present value of estimated future cash flows. Any changes to the carrying amount of the investment, including impairment losses, are recognized in the statement of comprehensive loss. The Company has not classified any financial assets as held-to-maturity investments.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

**a) Financial instruments (continued)**

**i) Financial assets (continued)**

**(d) Available-for-sale**

Non-derivative financial assets not included in the above categories are classified as available-for-sale. They are carried at fair value with changes in fair value recognized directly in other comprehensive income or loss ("OCI"). Where a decline in the fair value of an available-for-sale financial asset constitutes objective evidence of impairment, the amount of the loss is removed from OCI and recognized in the statement of comprehensive loss. The Company has not classified any assets as an available-for-sale asset.

Transaction costs associated with fair value through profit or loss financial assets are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset.

All financial assets except for those at fair value through profit or loss are subject to review for impairment at least at each reporting date. Financial assets are impaired when there is any objective evidence that a financial asset or a group of financial assets is impaired. Different criteria to determine impairment are applied for each category of financial assets, which are described above.

**ii) Financial liabilities**

The Company classifies its financial liabilities into one of two categories depending on the purpose for which the liability was incurred. The Company's accounting policy for each category is as follows:

**(a) Fair value through profit or loss**

This category comprises derivatives or liabilities acquired or incurred principally for the purpose of selling or repurchasing in the near term. They are carried in the statements of financial position at fair value, with changes in fair value recognized in the statements of comprehensive loss. The Company has not classified any financial liabilities as fair value through profit and loss.

**(b) Other financial liabilities**

This category includes accounts payable and accrued liabilities which are recognized at amortized cost using the effective interest rate method. The effective interest rate method is a method for calculating the actual interest rate in a period based on the amount of a financial instrument's book value at the beginning of the accounting period. The Company has classified accounts payable and accrued liabilities, promissory notes payable, mortgages payable, and advances from related parties as other financial liabilities.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

**b) Cash**

Cash in the statement of financial position is comprised of cash at banks and on hand which are readily convertible into a known amount of cash.

**c) Biological assets and inventory**

The Company's biological assets and inventory will include: biological assets which are marijuana plants that are being cultivated to be harvested for their flowers, which are subsequently dried to produce the finished product and include the harvest-in-process and its mother plants; agricultural produce which are harvested marijuana flowers prior to completion of the drying, grading, and testing processes; and finished product which are purchased materials and packaged marijuana.

The value of biological assets is measured on initial recognition and at the end of each reporting period at their fair value less costs to sell, unless the Company is unable to reliably measure the fair value thereof as prescribed by IAS 41 (paragraph 30) as amended.

The value of agricultural produce is measured on initial recognition at its fair value less costs to sell at the point of harvest. The value of finished goods is measured at the lower of cost or net realizable value, wherein the cost of the dried marijuana contained therein includes the value of the agricultural produce at the date of its conversion.

Any write down of inventories to net realizable value if below cost are recorded in the statement of loss and comprehensive loss at the time they are determined.

**d) Property and equipment**

Property and equipment are carried at cost less accumulated depreciation and accumulated impairment losses.

The cost of an item of property and equipment consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use, and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located.

An item of equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the statement of comprehensive loss.

Where an item of equipment comprises major components with different useful lives, the components are accounted for as separate items of property and equipment. Expenditures incurred to replace a component of an item of property and equipment that is accounted for separately, including major inspection and overhaul expenditures, are capitalized.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**4. SIGNIFICANT ACCOUNTING POLICIES** (continued)

**d) Property and equipment** (continued)

IAS 41, as amended, requires that bearer plants be recognized as property and equipment. A bearer plant is a living plant used in the production or supply of agricultural produce and is expected to bear produce for more than one period and has a remote likelihood of being sold as agricultural produce except for incidental scrap sales. Mother plants which are used for cuttings to initiate the marijuana growing process have a useful life of approximately a year; accordingly, mother plants are not considered bearer plants. Mother plants are recognized as biological assets.

Equipment is depreciated annually at the following rates using the declining-balance method when the asset becomes available for use, and in the year of acquisition, only one-half of normal rates are used:

Buildings	4%
Computer equipment	55%
Warehouse and office equipment	20%
Furniture and fixtures	20%
Software	100%

**e) Impairment**

At each financial position reporting date, the carrying amounts of the Company's long lived assets are reviewed to determine whether there is any indication that those assets are impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

An asset's recoverable amount is the higher of fair value less costs to sell, and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessment of the time value of money and the risks specific to the asset. If the recoverable amount of an asset or cash generating unit is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in the statement of comprehensive loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset or cash-generating unit is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset or cash-generating unit in prior years. A reversal of an impairment loss is recognized immediately in the statement of comprehensive loss.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

**f) Share capital**

**i) Common shares**

Common shares are classified as equity. Transaction costs directly attributable to the issue of common shares and share options are recognized as a deduction from equity, net of any tax effects.

**ii) Equity units**

Proceeds received on the issuance of units comprised of common shares and warrants are allocated on the residual value method where proceeds are allocated to the common shares up to their fair value as determined by the current quoted trading price on the announcement date, and the balance, if any, to the reserve for the warrants.

**iii) Non-monetary consideration**

Where share capital is issued, or received, as non-monetary consideration and the fair value of the asset received or given up is not readily determinable, the fair market value of the shares is used to record the transaction. The fair market value of the shares is based on the trading price of those shares on the appropriate stock exchange on the date of the agreement to issue or receive shares as determined by the board of directors.

**g) Share-based compensation**

The share option plan allows Company employees and consultants to acquire shares of the Company. The fair value of share options granted to employees is recognized as an expense over the vesting period with a corresponding increase in equity. An individual is classified as an employee when the individual is an employee for legal or tax purposes (a direct employee) or provides services similar to those performed by a direct employee (a consultant). The fair value is measured at grant date and recognized over the period during which the options vest.

The fair value of the options granted to employees is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted. At each financial position reporting date, the amount recognized as an expense is adjusted to reflect the actual number of share options that are expected to vest.

The fair value of share options granted to non-employees is recognized as an expense in the statement of comprehensive loss and is recorded at the fair value of the services received, unless they are related to the issuance of shares. The amount related to the issuance of shares is recorded as a reduction of share capital.

When the value of services received in exchange for the share-based compensation cannot be reliably estimated, the fair value is measured by use of a valuation model. The expected life used in the model is adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations.



---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

**g) Share-based compensation (continued)**

All share-based compensation is reflected in reserves until exercised. Upon exercise, shares are issued from treasury and the amount reflected in reserves is credited to share capital, adjusted for any consideration paid.

**h) Equity reserves**

Where share options or warrants expire or are cancelled, the fair value previously recognized is transferred from the equity reserve to accumulated deficit.

**i) Loss per share**

The Company presents basic and diluted loss per share data for its common shares, calculated by dividing the loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all dilutive potential common shares.

**j) Provisions**

Provisions are recognized where a legal or constructive obligation has been incurred as a result of past events; it is probable that an outflow of resources embodying economic benefit will be required to settle the obligation; and a reliable estimate of the amount of the obligation can be made. If material, provisions are measured at the present value of the expenditures expected to be required to settle the obligation.

**k) Revenue recognition**

Revenue arises from the sale of goods and the rendering of services. It is measured at the fair value of consideration received or receivable, excluding sales taxes, and reduced by any rebates and trade discounts allowed.

Revenue generated from providing consulting services is recognized as revenue in the period in which the service is performed. Where payment is received in advance of providing the service, the amount received is recognized as deferred revenue.

Revenue from the sale of goods in the course of ordinary activities is measured at the fair value of the consideration received or receivable, net of returns, trade discounts and volume rebates. Sales revenue is recognized when persuasive evidence exists, usually in the form of an executed sales agreement, that the significant risks and rewards of ownership have been transferred to the customer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. The transfer of risks and rewards occurs when the product is received by the customer.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

**l) Income taxes**

Income tax on the profit or loss for the years presented comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized as equity.

Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the year end, adjusted for amendments to the tax payable with regards to previous years.

Deferred tax is provided using the liability method providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes; the initial recognition of assets or liabilities in a transaction that is not a business combination and that affect neither accounting nor taxable profit; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the statement of financial position date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

Additional income taxes that arise from the distribution of dividends are recognized at the same time as the liability to pay the related dividend.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

**m) Segment reporting**

The Company operates in a single reportable segment being the scientific research and development, and proposed cultivation of medical marijuana.

**n) New accounting standards and interpretations not yet adopted**

The following accounting pronouncement has been released but has not yet been adopted by the Company:

**IFRS 9 *Financial Instruments***

In November 2009, the IASB issued, and subsequently revised in October 2010, IFRS 9 *Financial Instruments* (IFRS 9) as a first phase in its ongoing project to replace IAS 39. IFRS 9, which is to be applied retrospectively, is effective for annual periods beginning on or after January 1, 2018, with earlier application permitted.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

For the Six Months Ended January 31, 2016

---

**4. SIGNIFICANT ACCOUNTING POLICIES** (continued)

**n) New accounting standards and interpretations not yet adopted** (continued)

**IFRS 9 *Financial Instruments*** (continued)

IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. The new standard also requires a single impairment method to be used, replacing the multiple impairment methods in IAS 39. The standard also adds guidance on the classification and measurement of financial liabilities. Management has not yet determined the potential impact the adoption of IFRS 9 will have on the Company's financial statements.

**IFRS 15 *Revenue Recognition***

In May 2014, the IASB issued IFRS 15 *Revenue from Contracts with Customers* (IFRS 15). The new standard provides a comprehensive five-step revenue recognition model for all contracts with customers and requires management to exercise significant judgment and make estimates that affect revenue recognition. IFRS 15 is effective for annual periods beginning on or after January 1, 2017, with earlier adoption permitted. Management has not yet determined the potential impact the adoption of IFRS 15 will have on the Company's financial statements.

**5. INVESTMENT HELD FOR SALE**

Number of Shares	January 31, 2016		July 31, 2015	
	Cost	FMV	Cost	FMV
315,000 Zadar Ventures Ltd.	\$ -	\$ -	\$ 81,900	\$ 3,150

On September 25, 2013, Thelon sold its 18% interest in the Pasfield Lake property which was part of the Athabasca Basin property which was previously written down, to Zadar Ventures Ltd., a company with common directors, for gross proceeds of \$25,000 cash and 315,000 common shares of Zadar Ventures Ltd. The 315,000 common shares of Zadar Ventures Ltd. were issued to Thelon on October 2, 2013 and sold on January 28, 2016 for net proceeds of \$4,725.

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

For the Six Months Ended January 31, 2016

**6. PROPERTY AND EQUIPMENT**

	Land	Buildings	Warehouse and Lab Equipment	Warehouse and Lab Computer Equipment	Office Furniture Equipment	Office Computer Equipment	Software	Total
<b>Cost</b>								
Balance, July 31, 2014	\$ 181,577	\$ 255,026	\$ 6,612	\$ 5,001	\$ 2,087	\$ 1,326	\$ -	\$ 451,629
Additions	225,030	325,913	15,679	23,358	5,301	-	1,093	596,374
Balance, July 31, 2015	406,607	580,939	22,291	28,359	7,388	1,326	1,093	1,048,003
Additions	10,174	42,306	5,430	-	-	-	-	57,910
<b>Balance, January 31, 2016</b>	<b>\$ 416,781</b>	<b>\$ 623,245</b>	<b>\$ 27,721</b>	<b>\$ 28,359</b>	<b>\$ 7,388</b>	<b>\$ 1,326</b>	<b>\$ 1,093</b>	<b>\$ 1,105,913</b>
<b>Accumulated Depreciation</b>								
Balance, July 31, 2014	\$ -	\$ -	\$ -	\$ 452	\$ 584	\$ 893	\$ -	\$ 1,929
Additions	-	-	1,349	8,722	831	238	546	11,686
Balance, July 31, 2015	-	-	1,349	9,174	1,415	1,131	546	13,615
Additions	-	-	599	5,276	597	54	274	6,800
<b>Balance, January 31, 2016</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 1,948</b>	<b>\$ 14,450</b>	<b>\$ 2,012</b>	<b>\$ 1,185</b>	<b>\$ 820</b>	<b>\$ 20,415</b>
<b>Carrying Amounts</b>								
Balance, July 31, 2015	\$ 406,607	\$ 580,939	\$ 20,942	\$ 19,185	\$ 5,973	\$ 195	\$ 547	\$ 1,034,388
<b>Balance, January 31, 2016</b>	<b>\$ 416,781</b>	<b>\$ 623,245</b>	<b>\$ 25,773</b>	<b>\$ 13,909</b>	<b>\$ 5,376</b>	<b>\$ 141</b>	<b>\$ 273</b>	<b>\$ 1,085,498</b>

The Company acquired the first property to house their warehouse and laboratory facilities in September of 2012 for \$291,526, of which \$162,140 was attributed to the land and \$129,386 to the building. All costs of modifications to the property to meet all specifications required by Health Canada have been capitalized to date along with the mortgage interest. For the six months ended January 31, 2016, mortgage interest of \$4,156 (July 31, 2015 - \$8,302) was capitalized for the land and \$3,152 (July 31, 2015 - \$6,296) for the building.

The Company acquired the second property to expand their warehouse facilities on October 2, 2014 for cash and mortgage payable totaling \$341,604, of which \$199,326 was attributed to the land and \$142,278 to the building. All costs of modifications to the property to meet all specifications required by Health Canada have been capitalized to date along with the mortgage interest. For the six months ended January 31, 2016, mortgage interest of \$6,017 (July 31, 2015 - \$14,653) was capitalized for the land and \$4,295 (July 31, 2015 - \$8,472) for the building.

Depreciation will begin when the buildings are in use pending the receipt of a MMPR license from Health Canada.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**7. MORTGAGES PAYABLE**

The Company has a mortgage payable on its first property in the principal amount of \$210,560 with interest at 5.50% per annum with monthly payments of \$2,760 due on the 21st day of each month. The mortgage originally matured on September 21, 2015. On March 31, 2015, the mortgage was modified to mature on August 21, 2018 with interest at 10% per annum starting on September 22, 2015. At January 31, 2016, the balance payable is \$194,927 (July 31, 2015 - \$203,317) including accrued interest.

The Company has a mortgage payable on its second property in the principal amount of \$250,000 with interest at 10% per annum with monthly payments of \$2,656 due on the 2nd day of each month. The first payment was on November 2, 2014 and the mortgage matures on October 2, 2017. At January 31, 2016, the balance payable is \$240,945 (July 31, 2015 - \$246,567) including accrued interest.

**8. PROMISSORY NOTE PAYABLE**

The Company issued a promissory note in the principal amount of up to \$150,000 on December 31, 2014 to BUA Capital Management Ltd., a private company controlled by a director, Jason Walsh. The note is without interest and due on December 31, 2016. At January 31, 2016, \$135,000 (July 31, 2015 - \$150,000) is owed against the note.

**9. SHARE CAPITAL**

**a) Common shares**

**Authorized:**

Unlimited number of common shares without par value

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

**For the Six Months Ended January 31, 2016**

**9. SHARE CAPITAL (continued)**

**a) Common shares (continued)**

**Issued:**

	<b>Number</b>	<b>Issued Price</b>	<b>Amount</b>
Balance at July 31, 2014	23,040	\$ -	\$ 138,221
Shares issued as a private company, net of share issuance costs	4,546	-	754,400
Shares issued on restructuring	56,948,660	-	-
Shares issued for acquisition of Thelon Capital Ltd.	18,698,374	0.045	841,427
Balance at July 31, 2015	75,674,620	-	1,734,048
Shares issued for cash	10,925,000	-	1,115,500
Shares issued for debt	6,359,924	-	706,516
Shares issued for finder fees	240,000	-	23,400
Share issuance costs	-	-	(62,300)
<b>Balance at January 31, 2016</b>	<b>93,199,544</b>	<b>\$ -</b>	<b>\$ 3,517,164</b>

For the year ended July 31, 2014, 11,520 common shares were issued for \$0.01 per share for gross proceeds of \$115, and 720 common shares were issued for \$208.33 per share for gross proceeds of \$149,998. A finder's fee of 8% was paid in the amount of \$12,000.

On August 4, 2014, 240 common shares were issued for \$0.01 per share for gross proceeds of \$2, and 240 common shares were issued at \$208.33 per share for gross proceeds of \$49,999. A finder's fee of 8% was paid in the amount of \$4,000.

On August 22, 2014, 240 common shares were issued for \$0.01 per share for gross proceeds of \$2.

On September 4, 2014, 240 common shares at \$208.33 per share for gross proceeds of \$49,999. A finder's fee of 8% was paid in the amount of \$4,000.

On September 29, 2014, 3,586 common shares at \$200.78 per share for gross proceeds of \$719,998. A finder's fee of 8% was paid in the amount of \$57,600.

On January 14, 2015, to effect the acquisition of Thelon (note 2) the Company implemented a share exchange whereby the former 27,586 common shares of the THC Companies were exchanged for 56,948,660 common shares of the Company.

On January 14, 2015, Thelon had 18,698,364 common shares outstanding prior to the RTO.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**9. SHARE CAPITAL** (continued)

**a) Common shares** (continued)

On October 26, 2015, the Company closed a non-brokered private placement of 4,119,583 units ("Unit) at a price of \$0.06 per Unit for gross proceeds of \$190,500 and settled \$56,675 of short term debt. Each Unit consists of one common share and one common share purchase warrant exercisable at \$0.15 per share until October 26, 2016. The warrants will have an acceleration clause such that, if after the required hold period, the shares in the Company trade above \$0.20 for 10 consecutive trading days, the Company will notify the warrant holders that they have 30 days to exercise the warrants from the date that such notice is given. A finder's fee of \$2,900 was paid in cash along with 90,000 Units on the same terms for the private placement.

On November 6, 2015, the Company issued 4,660,000 common shares pursuant to a settlement agreement with Jacob Securities Inc. The shares were issued at a fair value of \$0.12 per share and will be released pursuant to a stock restriction agreement over the course of 36 months. The value of the shares of \$559,200 was recorded as consulting fees and previously included in accounts payable and accrued liabilities.

On December 9, 2015, 250,000 stock options were exercised at \$0.10 per share for gross proceeds of \$25,000.

On December 10, 2015, the Company closed a non-brokered private placement of 7,500,000 units ("Unit) at a price of \$0.12 per Unit for gross proceeds of \$900,000. Each Unit consists of one common share and one common share purchase warrant exercisable at \$0.25 per share until December 10, 2016. The warrants will have an acceleration clause such that, if after the required hold period, the shares in the Company trade above \$0.30 for 10 consecutive trading days, the Company will notify the warrant holders that they have 30 days to exercise the warrants from the date that such notice is given. A finder's fee of \$36,000 was paid in cash along with 150,000 Units on the same terms for the private placement.

On December 10, 2015, the Company issued 755,341 common shares at \$0.12 per share to settle \$90,641 in debt.

**b) Escrow shares**

Currently 690 common shares (July 31, 2015 – 690) are held in escrow.

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

For the Six Months Ended January 31, 2016

**9. SHARE CAPITAL** (continued)

**c) Warrants outstanding**

	Number of Warrants	Weighted Average Exercise Price
Warrants issued	8,416,666	\$ 0.30
Warrants exercised	(3,183,333)	0.30
Balance at July 31, 2015	5,233,333	0.60
Warrants issued	11,859,583	0.21
<b>Balance at January 31, 2016</b>	<b>17,092,916</b>	<b>\$ 0.33</b>

Expiry Date	Remaining Life (Years)	Number of Warrants	Exercise Price
September 25, 2016	0.65	5,233,333	\$ 0.60
October 26, 2016	0.74	4,209,583	\$ 0.15
December 10, 2016	0.86	7,650,000	\$ 0.25
		17,092,916	\$ 0.33

On September 25, 2013, Thelon closed a non-brokered private placement of 8,416,666 units at \$0.03 per unit for gross proceeds of \$252,500. Each unit consisted of one common share and one warrant of the Company. Each warrant is exercisable to purchase one common share of the Company until September 25, 2016, at \$0.30 per share until February 25, 2015 and at \$0.60 during the remaining period. On March 19, 2015, the warrants which were exercisable at \$0.30 per share until February 25, 2015 were extended to be exercisable at \$0.30 per share until September 25, 2015 and then at \$0.60 per share until September 25, 2016.

**10. SHARE-BASED COMPENSATION**

The Company is authorized to grant options to directors, officers, and employees to acquire common shares. The Company's previous stock option plan was cancelled and the Company has adopted the 2015 Stock Option Incentive Plan (the "Plan"). The essential elements of the Plan provide that the aggregate number of shares of the Company's capital stock issuable pursuant to options granted under the Plan may not exceed 10% of the issued common shares of the Company from time to time. Options granted under the Plan may have a maximum term of ten (10) years. The exercise price of options granted under the Plan will not be less than the fair market value price of the shares on the date of grant of the options (defined as the last closing market price of the Company's shares on the last day shares are traded prior to the grant date). Stock options granted under the Plan vest immediately subject to vesting terms which may be imposed at the discretion of the Directors.



**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

**For the Six Months Ended January 31, 2016**

**10. SHARE-BASED COMPENSATION** (continued)

The following summarizes the stock options outstanding:

	Number of Options	Weighted Average Exercise Price
Options granted	4,083,334	\$ 0.30
Balance at July 31, 2015	4,083,334	0.30
Options granted	1,000,000	0.10
Options cancelled	(458,333)	0.60
Options exercised	(250,000)	0.10
<b>Balance at January 31, 2016</b>	<b>4,375,001</b>	<b>\$ 0.24</b>

Date of Grant	Expiry Date	Remaining Life (Years)	Number of Options Exercisable	Number of Options Outstanding	Exercise Price
April 10, 2014	April 10, 2016	0.19	1,125,001	1,125,001	\$ 0.60
July 10, 2015	July 10, 2017	1.44	250,000	750,000	\$ 0.13
July 22, 2015	July 22, 2017	1.48	250,000	500,000	\$ 0.13
July 28, 2015	July 28, 2017	1.49	1,000,000	1,000,000	\$ 0.10
October 5, 2015	October 5, 2017	1.68	1,000,000	1,000,000	\$ 0.10
			3,625,001	4,375,001	\$ 0.24

On April 10, 2014, Thelon granted 1,583,334 stock options to certain officers, directors, and consultants of the Company to acquire 1,583,334 common shares of the Company at an exercise price of \$0.60 per share, with an expiry date of April 10, 2016. 166,667 options granted to Star Finance GmbH for investor relation services vested over a 12 month period and have a fair value, calculated using the Black-Scholes option pricing model, of \$32,009 or \$0.19 per option, assuming an expected life of 2 years, a risk-free interest rate of 1.05%, an expected dividend rate of 0.00%, and an expected annual volatility coefficient of 236%. The 1,416,667 options have a fair value, calculated using the Black-Scholes option pricing model, of \$709,422 or \$0.50 per option, assuming an expected life of two years, a risk-free interest rate of 1.05%, an expected dividend rate of 0.00%, and an expected annual volatility coefficient of 161%.

On July 10, 2015, Thelon granted 1,000,000 stock options to a consultant of the Company to acquire 1,000,000 common shares of the Company with an expiry date of July 10, 2017. 500,000 stock options have an exercise price of \$0.10 per share and 500,000 stock options have an exercise price of \$0.15 per share. The options vest over the course of one year with 25% vesting on the date of grant and 25% every four months following the date of grant. The options have a fair value, calculated using the Black-Scholes option pricing model, of \$20,699 or \$0.02 per option, assuming an expected life of 2 years, a risk-free interest rate of 0.50%, an expected dividend rate of 0.00%, and an expected annual volatility coefficient of 147%.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**10. SHARE-BASED COMPENSATION** (continued)

On July 22, 2015, Thelon granted 500,000 stock options to a consultant of the Company to acquire 500,000 common shares of the Company with an expiry date of July 22, 2017. 250,000 stock options have an exercise price of \$0.10 per share and 250,000 stock options have an exercise price of \$0.15 per share. The options vest over the course of one year with 25% vesting on the date of grant and 25% every four months following the date of grant. The options have a fair value, calculated using the Black-Scholes option pricing model, of \$29,107 or \$0.06 per option, assuming an expected life of 2 years, a risk-free interest rate of 0.43%, an expected dividend rate of 0.00%, and an expected annual volatility coefficient of 158%.

On July 28, 2015, Thelon granted 1,000,000 stock options to consultants of the Company to acquire 1,000,000 common shares of the Company with an expiry date of July 28, 2017. The options have a fair value, calculated using the Black-Scholes option pricing model, of \$44,018 or \$0.04 per option, assuming an expected life of 2 years, a risk-free interest rate of 0.44%, an expected dividend rate of 0.00%, and an expected annual volatility coefficient of 158%.

On October 5, 2015, Thelon granted 1,000,000 stock options to employees of the Company to acquire 1,000,000 common shares of the Company with an expiry date of October 5, 2017. The options have a fair value, calculated using the Black-Scholes option pricing model, of \$41,546 or \$0.04 per option, assuming an expected life of 2 years, a risk-free interest rate of 0.51%, an expected dividend rate of 0.00%, and an expected annual volatility coefficient of 165%.

**11. RELATED PARTY TRANSACTIONS**

The Company has identified certain directors and senior officers as key management personnel. The following table lists the compensation costs paid to key management personnel and companies owned by key management personnel for the three months ended January 31, 2016 and 2015:

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

For the Six Months Ended January 31, 2016

**11. RELATED PARTY TRANSACTIONS (continued)**

	Accounting	Consulting	Office and Administration	Salaries and Benefits	January 31, 2016 Total
BUA Capital Management Ltd. \$	-	\$ 45,000	\$ -	\$ -	\$ 45,000
BUA Group Holdings Ltd.	-	-	24,600	-	24,600
GRW Inc.	-	12,000	-	-	12,000
Hee Jung Chun	-	-	-	31,200	31,200
John Miller	-	-	-	100,200	100,200
PubliCo Services Ltd.	-	5,000	-	-	5,000
T. St. Denis, Inc.	48,725	-	-	-	48,725
	<b>\$ 48,725</b>	<b>\$ 62,000</b>	<b>\$ 24,600</b>	<b>\$ 131,400</b>	<b>\$ 266,725</b>

  

	Accounting	Consulting	Office and Administration	Salaries and Benefits	January 31, 2015 Total
BUA Capital Management Ltd. \$	-	\$ 4,355	\$ -	\$ -	\$ 4,355
BUA Group Holdings Ltd.	-	-	2,381	-	2,381
GRW Inc.	-	1,742	-	-	1,742
Hee Jung Chun	-	-	-	33,790	33,790
John Miller	-	-	-	33,790	33,790
	<b>\$ -</b>	<b>\$ 6,097</b>	<b>\$ 2,381</b>	<b>\$ 67,580</b>	<b>\$ 76,058</b>

BUA Capital Management Ltd. provides consulting services to the Company and is a private company controlled by a director, Jason Walsh. On October 26, 2015, BUA Capital Management Ltd. was issued 250,000 Units (note 9a) at \$0.06 for \$15,000 in debt. At January 31, 2016, the Company owed \$52,183 (July 31, 2015 - \$4,933) to BUA Capital Management Ltd. which is included in advances from related parties, and \$135,000 (July 31, 2015 - \$150,000) which is included in long term promissory note payable.

BUA Group Holdings Ltd. provides administration services to the Company and is a private company controlled by a director, Jason Walsh. At January 31, 2016, the Company was owed \$1,651 (July 31, 2015 - \$Nil) from BUA Group Holdings Ltd. which is included in advances to related parties.

Jason Walsh is a director and Chairman of the Company. At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$25,000) to Mr. Walsh for unpaid director fees which were written off as part of debt settlement. At January 31, 2016, the Company is owed \$2,249 (July 31, 2015 - \$(24,849)) from Mr. Walsh which is included in the advances to related parties.

Geoff Watson is the former Chief Financial Officer and a former director of the Company. At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$26,000) to Mr. Watson for unpaid director fees which were written off as part of debt settlement.

---

**THC BIOMED INTL LTD.**  
**(formerly Thelon Capital Ltd.)**

**Notes to the Condensed Interim Consolidated Financial Statements**  
**(Expressed in Canadian Dollars)**  
**(Unaudited)**

---

**For the Six Months Ended January 31, 2016**

---

**11. RELATED PARTY TRANSACTIONS (continued)**

GRW Inc. provided consulting services to the Company and is a private company controlled by the former Chief Financial Officer, Geoff Watson. At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$12,037) to GRW Inc. which was previously included in advances from related parties as the Company paid \$24,637 in December, 2015 for the full amount owing. At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$30,543) which was previously included in long term promissory notes payable as the Company issued 254,529 common shares to GRW Inc. pursuant to a debt settlement in December, 2015.

Hee Jung Chun is a director of the Company and co-founder of the THC Companies. Ms. Chun receives a salary from the THC Companies. At January 31, 2016, \$5,200 (July 31, 2015 - \$31,200) is owed and included in accounts payable and accrued liabilities.

John Miller is the President of the Company, a director, and co-founder of the THC Companies. Mr. Miller receives a salary from the THC Companies; at January 31, 2016, \$5,200 (July 31, 2015 - \$31,200) is owed and included in accounts payable and accrued liabilities. He also receives a salary from Thelon; at January 31, 2016, \$Nil (July 31, 2015 - \$35,000) is owed as previously included in accounts payable and accrued liabilities. At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$63,403) to Mr. Miller which was previously included in long term promissory notes payable as the Company paid the amount in full in December 2015. On October 26, 2015, Mr. Miller was issued 208,333 Units (note 9a) at \$0.06 for \$12,500 of debt; at January 31, 2016, \$16,071 (July 31, 2015 - \$Nil) was owed to Mr. Miller and included in advances from related parties.

PubliCo Services Ltd. provides compliance services to the Company and is a private company owned by the Corporate Secretary, Dianne Szigety.

T. St. Denis, Inc. is a private accounting firm owned by the Chief Financial Officer, Tracey A. St. Denis. T. St. Denis, Inc. provides accounting services to the Company. On October 26, 2015, T. St. Denis, Inc. was issued 250,000 Units (note 9a) at \$0.06 for \$15,000 of debt. At January 31, 2016, the Company owed \$18,661 (July 31, 2015 - \$55,165) to T. St. Denis, Inc. which is included in accounts payable and accrued liabilities. At January 31, 2016, \$12,550 (July 31, 2015 - \$20,500) is also included in accounts payable and accrued liabilities relating to the accounting accrual for the current period.

Hardcastle Capital Partners Corp. provided consulting services to the Company and is a private company controlled by the former President and Chief Executive Officer, Scott Walters. At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$6,500) to Hardcastle Capital Partners Corp. which was previously included in advances from related parties as the Company paid \$3,250 pursuant to a debt settlement in December, 2015.

International Ranger Corp. is a public company with common directors. At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$19,840) to International Ranger Corp. which was previously included in long term promissory notes payable as the Company paid \$7,839 and issued 65,328 shares (see note 9a) pursuant to a debt settlement in December, 2015. At January 31, 2016, the Company is owed \$1,713 (July 31, 2015 - \$Nil) from International Ranger Corp. which is included in advances to related parties.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**11. RELATED PARTY TRANSACTIONS (continued)**

Scout Exploration Inc. is a public company with common directors. At January 31, 2016, the Company owed \$Nil (July 31, 2015 – \$3,955) to Scout Exploration Inc. which was previously included in advances from related parties which was paid in December, 2015.

Thelon Diamond Company Limited is a public company with common directors controlled by Jason Walsh, At January 31, 2016, the Company owed \$Nil (July 31, 2015 - \$72,350) to Thelon Diamond Company Limited which was previously included in promissory notes payable and paid in December, 2015, and \$1,000 (July 31, 2015 - \$22,892) which is included in advances from related parties.

At January 31, 2016, the Company owed \$5,500 (July 31, 2015 - \$Nil) to Thelon Diamonds Ltd., a private company controlled by a director of the Company, Jason Walsh. The amount is included in advances from related parties.

At January 31, 2016, the Company was owed \$5,753 (July 31, 2015 - \$10,453) from 1177129 Alberta Ltd., a private company controlled by a director of the Company, Jason Walsh. The amount is included in advances to related parties.

At January 31, 2016, the Company was owed \$66 (July 31, 2015 -\$66) from 782618 B. C. Ltd., a private company controlled by a director of the Company, Jason Walsh. The amount is included in advances to related parties.

At January 31, 2016, the Company was owed \$613 (July 31, 2015 - \$613) from United Zeolite Ltd., a private company with common directors. The amount is included in advances to related parties.

At January 31, 2016, the Company was owed \$89,009 (July 31, 2015 - \$89,472) from Zadar Ventures Ltd., a public company with common directors. The amount is included in advances to related parties.

Amounts due to or from related parties are unsecured, do not bear interest, and are classified as a current asset or liability due to their nature and expected time of repayment; accordingly the fair value cannot be practicably determined.

**12. SEGMENTED INFORMATION**

The Company operates in a single reportable segment being the scientific research and development, and cultivation of medical marijuana.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

For the Six Months Ended January 31, 2016

---

**13. SUPPLEMENTAL CASH FLOW INFORMATION**

	January 31 2016	January 31 2015
Income taxes paid	\$ -	\$ -
Interest paid	\$ 68,446	\$ 14,488
Interest received	\$ 35	\$ -

**14. OPERATING LEASE COMMITMENTS**

The Company signed a 36 month lease for high performance liquid chromatography equipment for the laboratory. The lease began on October 31, 2013 with monthly payments of \$2,651.

The Company signed a 36 month lease for a Toyota Matrix. A vehicle is to be available to the Quality Assurance person at all times to conduct their duties and in case of an emergency, as stipulated in the MMPR. The lease began on September 3, 2013 with monthly payments of \$430.

The Company signed a 36 month lease for a Toyota Venza. A vehicle is to be available to the Responsible Person in Charge at all times in case of an emergency, as stipulated in the MMPR. The lease began on October 1, 2014 with monthly payments of \$757.

**15. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT**

**a) Fair value of financial instruments**

The carrying values of cash, amounts receivable, investments held for sale, advances due to/from related parties, accounts payable and accrued liabilities, and current promissory notes payable approximate their carrying values due to the immediate or short-term nature of these instruments.

**b) Fair value hierarchy**

IFRS 7, Financial Instruments: Disclosures, establishes a fair value hierarchy that prioritizes the input to valuation techniques used to measure fair value as follows:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The investment held for sale has been valued using a Level 1 valuation technique.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**15. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)**

**c) Financial risk management**

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

**i) Credit risk**

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to credit risk consist primarily of cash and amounts due from related parties. The Company limits its exposure to credit risk by placing its cash with a high credit quality financial institution in Canada. The Company's financial assets are not subject to material financial risks.

**ii) Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet commitments associated with financial instruments, property exploration and development, or the proposed transactions. The Company manages liquidity risk by maintaining adequate cash balances.

The Company's expected source of cash flow in the upcoming year will be through debt or equity financing. Cash on hand at January 31, 2016 and expected cash flows for the next 12 months are not sufficient to fund the Company's ongoing operational needs. The Company will need funding through equity or debt financing, entering into joint venture agreements, or a combination thereof.

**iii) Market risk**

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, and commodity and equity prices.

**(a) Interest rate risk**

Interest rate risk consists of two components: to the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk; and to the extent that changes in prevailing market rates differ from the interest rate in the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

Current financial assets and financial liabilities are generally not exposed to interest rate risk because of their short-term nature, fixed interest rates, and maturity. The Company is exposed to interest rate price risk as its promissory notes bear interest at fixed rates.

---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**15. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)**

**c) Financial risk management (continued)**

**iii) Market risk (continued)**

**(b) Foreign currency risk**

Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency.

At January 31, 2016, the Company is exposed to foreign currency risk with respect to its US denominated bank accounts. At January 31, 2016, financial instruments were converted at a rate of \$1.00 Canadian to US\$1.408.

The Company has not entered into any foreign currency contracts to mitigate foreign currency risk.

**(c) Capital risk management**

The Company manages its capital to ensure that it will be able to continue as a going concern while maximizing the return to stakeholders through a suitable debt and equity balance appropriate for an entity of the Company's size and status. The Company's overall strategy remains unchanged from last year.

The capital structure of the Company consists of equity attributable to common shareholders, comprised of issued capital, warrants, reserves, and deficit. The availability of new capital will depend on many factors including positive stock market conditions, the Company's track record, and the experience of management. The Company is not subject to any external covenants on its capital.

**(d) Price risk**

Price risk is the risk that the fair value of investments will decline below the cost of the underlying investments. The Company is exposed to price risk regarding its investments held for sale. The Company manages this price risk by monitoring the investment on a regular basis.



---

**THC BIOMED INTL LTD.**  
(formerly Thelon Capital Ltd.)

**Notes to the Condensed Interim Consolidated Financial Statements**  
(Expressed in Canadian Dollars)  
(Unaudited)

---

**For the Six Months Ended January 31, 2016**

---

**16. SUBSEQUENT EVENTS**

On February 4, 2016, 2,000,000 common shares were issued to Cervus Business Management Inc. pursuant to a settlement agreement with a fair value of \$0.12 per share. The shares will be released pursuant to a stock restriction agreement over the course of 36 months. The value of the shares of \$240,000 was recorded as consulting fees and is included in accounts payable and accrued liabilities at January 31, 2016.

On March 22, 2016, the Company announced it had entered into a joint venture agreement with Supra Research and Development Inc. ("Supra") to create Supra THC Services Inc. ("Supra THC"), a Health Canada licensed cannabis testing lab. Under the terms of the agreement, the Company will purchase 49% of the Supra THC for 2,500,000 common shares of which 2,000,000 common shares will be placed in escrow of which 1,900,000 common shares will be placed under a 36-month stock restriction agreement and released following the issuance date in accordance with the standard release schedule provide in NI 46-201. THC will purchase an additional 31% for \$600,000 on or before January 31, 2017. Pursuant to the agreement, the Company has a standard right of refusal to purchase the remaining 20% of Supra THC for 12 months following the purchase of the 31%. Prior to closing, Supra will have completed all necessary documentation to transfer to Supra THC certain intellectual property and specific equipment. Supra is also obliged to use all commercially reasonable efforts to develop a viable, commercially competitive extraction method for cannabis for Supra THC's use within six months of entry into the Agreement. When this occurs, the Company will issue an additional 600,000 shares to Supra pursuant to the agreement.

On March 24, 2016, 500,000 stock options were exercised at \$0.10 per share for gross proceeds of \$50,000.